[Translation] A Phase II, randomized, adaptive, open-label platform trial evaluating the efficacy and safety of multiple combination therapies in subjects with chronic hepatitis B
目的是评估新分子化合物联合治疗在具有肝储备功能且无显著肝纤维化/肝硬化的慢性乙型肝炎受试者中的安全性、耐受性和疗效。
[Translation] The aim was to evaluate the safety, tolerability and efficacy of combination therapy with new molecular compounds in chronic hepatitis B subjects with hepatic reserve and without significant hepatic fibrosis/cirrhosis.